Neurocrine Biosciences (NBIX) Tops Q2 EPS by 127c ; Offers Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall St set for higher open as Democrats win Congress; data center stocks slide
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mail
Get Alerts NBIX Hot Sheet
Price: $164.85 --0%
Financial Fact:
Net income (loss): -36.89M
Today's EPS Names:
ATS, SICP, FTCO, More
Financial Fact:
Net income (loss): -36.89M
Today's EPS Names:
ATS, SICP, FTCO, More
Join SI Premium – FREE
Neurocrine Biosciences (NASDAQ: NBIX) reported Q2 EPS of $2.85, $1.27 better than the analyst estimate of $1.58. Revenue for the quarter came in at $959 million versus the consensus estimate of $877.34 million.
GUIDANCE:
Neurocrine Biosciences sees FY2026 revenue of $2.82-2.87 billion, versus the consensus of $3.79 billion.
For earnings history and earnings-related data on Neurocrine Biosciences (NBIX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- CPS Technologies (CPSH) Reports In-Line Q3 EPS
- Dolphin to Host Third Quarter 2026 Earnings Conference Call on Nov 10, 2026
- L.B. Foster (FSTR) Reports In-Line Q3 EPS ; Offers Guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
